Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells

Transplant Infectious Disease

Volumn 15, Issue 1, 2013, Pages 79-89

  Dirks, J ^a   Egli, A ^b,c   Sester, U ^a   Sester, M ^a   Hirsch, H H ^b,c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Blockade; Cytokines; Cytomegalovirus; Immunosuppression; PD 1; T cells

Indexed keywords

CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RANTES; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EX VIVO STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS TITRATION;

ADULT; AGED; ANTIBODIES, BLOCKING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; VIREMIA;

EID: 84873478163     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12025     Document Type: Article

References (24)

1. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24 (2): 339-371.
2. Sester M, Gärtner BC, Sester U. Monitoring of CMV specific T-cell levels after organ transplantation. J Lab Med 2008; 32 (3): 121-130.
3. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22 (1): 76-98.
4. Presser D, Sester U, Mohrbach J, Janssen M, Kohler H, Sester M. Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney Int 2009; 76 (5): 557-566.
5. Sester U, Gärtner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5 (6): 1483-1489.
6. Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88 (10): 1161-1168.
7. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 131 (6): 492-499.
8. La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197 (1): 25-33.
9. Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8: 1486-1497.
10. Stebbings R, Findlay L, Edwards C, et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179 (5): 3325-3331.
11. Larsen M, Sauce D, Deback C, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 2011; 7 (10): e1002328.
12. Zhang G, Li Z, Han Q, et al. Altered TNF-alpha and IFN-gamma levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infect Genet Evol 2011; 11 (7): 1624-1630.
13. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007; 7 (8): 1997-2005.
14. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
15. Nordoy I, Muller F, Nordal KP, Rollag H, Aukrust P, Froland SS. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 2000; 120 (2): 333-337.
16. Sadeghi M, Daniel V, Naujokat C, et al. Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation 2008; 86 (2): 275-285.
17. Essa S, Pacsa A, Raghupathy R, et al. Low levels of Th1-type cytokines and increased levels of Th2-type cytokines in kidney transplant recipients with active cytomegalovirus infection. Transplant Proc 2009; 41 (5): 1643-1647.
18. Essa S, Raghupathy R, Pacsa AS, El-Shazly A, Said T, Azizieh F. Th1-type cytokines production is decreased in kidney transplant recipients with active cytomegalovirus infection. J Med Virol 2000; 60 (2): 223-229.
19. Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65 (5): 476-485.
20. van de Berg PJ, Heutinck KM, Raabe R, et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis 2010; 202 (5): 690-699.
21. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000; 177: 236-245.
22. La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transpl Int 2011; 24 (9): 920-931.
23. Krishnan A, Zhou W, Lacey SF, Limaye AP, Diamond DJ, La Rosa C. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transpl Infect Dis 2010; 12 (4): 363-370.
24. Riley JL, June CH. The road to recovery: translating PD-1 biology into clinical benefit. Trends Immunol 2007; 28 (2): 48-50.